topics / مواضيع

19 minutes ago

أبيرانات 250 مجم، قرص

أبيرانات 250 مجم، قرص جديد عرض تقديمي صندوق يحتوي على 120 زجاجة الجرعة 250 ملجم الموزع أو الشركة المصنعة أمانيس فارما (أسهم فارما السابقة) تعبير أبيراتيرون صف علاجي العلاج الهرموني ومضادات الهرمونات الأخرى والعوامل ذات الصلة حالة تم تسويقه كود ATC L02BX03 الدفع مقابل المشاهدة 10411.00 درهم سعر المستشفى 10215.00 درهم تلوين أ المؤشرات يشار إليه بالاشتراك مع بريدنيزون أو بريدنيزولون من أجل: - علاج سرطان البروستاتا الحساس للهرمون النقيلي عالي الخطورة الذي تم تشخيصه حديثًا (mHSPC) لدى الرجال البالغين بالاشتراك مع العلاج بالحرمان من الأندروجين (ADT) (انظر القسم ... más información

topics / مواضيع21 minutes ago

Untitled

ABSTRACT The synergy between radiotherapy and immunotherapy in treating thoracic cancers presents a potent therapeutic advantage, yet it also carries potential risks. The extent and nature of cumulative cardiac toxicity remain uncertain, prompting the need to discern its mechanisms and devise effective mitigation strategies. Radiation alone or in combination with an anti- Programmed cell death protein1 (PD-1) antibody significantly reduced cardiac function in C57BL/6J mice, and this pathologic effect was aggravated by anti-PD-1 (anti-PD-1 + radiation). To examine the cellular... más información

topics / مواضيع23 minutes ago

Untitled

ABSTRACT Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations. Rivaroxaban and apixaban are a selective, direct factor Xa inhibitor used to treat venous thromboembolism (VTE), which is a frequent complication of NSCLC. Rivaroxaban and apixaban are substrates of CYP3A4, P-gp and BCRP, whereas almonertinib is an inhibitor of P-gp and BCRP. Rivaroxaban or apixaban are often prescribed together with al... más información

topics / مواضيع23 minutes ago

Untitled

ABSTRACT Treating cancer patients with deep venous thrombosis/venous thromboembolism (DVT/VTE) can be challenging as patients are frequently unable to receive the standard therapy of anticoagulation due to the increased risk of bleeding complications seen in this population. Similarly, the hesitation of interventionalists to use thrombolytic agents due to bleeding risks limits percutaneous intervention options as well. Further, outcome data and guidelines do not exist for oncologic patients and often treatment is tailored to patient-specific factors after multidisciplinary di... más información

topics / مواضيع24 minutes ago

Untitled

ABSTRACT Atrial fibrillation (AF) can increase thrombosis, especially arterial thrombosis, and some studies show that AF patients have a higher risk of developing pulmonary embolism (PE). The objective of our study is to investigate whether there is a direct causal effect of AF on PE. A two-sample Mendelian randomization (MR) approach was utilized to determine whether there is a causal relationship between AF and PE. European population-based consortia provided statistical data on the associations between Single Nucleotide Polymorphisms (SNPs) and relevant traits. The AF dat... más información

topics / مواضيع25 minutes ago

Untitled

ABSTRACT This study aims to summarize the available data and determine if the presence of venous thromboembolism (VTE) immune-related adverse event (irAE) in patients with immune checkpoint inhibitor (ICI) therapy is associated with improved treatment efficacy and clinical outcomes, which in turn was used to help optimize patient selection for anticoagulation therapy and inform rational treatment strategies for overcoming the mechanisms of ICI resistance. PubMed, Embase, Web of Science, and Cochrane Library were searched up to March 18, 2023, for studies assessing the relati... más información